Effect of supplementation in treatment of polycystic ovary syndrome
Phase 3
- Conditions
- Polycystic ovary syndrome.Sclerocystic ovary syndrome Stein-Leventhal syndromeE28.2
- Registration Number
- IRCT201309275623N10
- Lead Sponsor
- Kashan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 104
Inclusion Criteria
Patients with PCOS according to Rotterdam criteria
Aged 18 to 40 years
Exclusion Criteria
Neoplastic
Hepatic disorders
Renal or cardiovascular disorders
Malabsorptive disorders
Taking calcium and vitamin D within the last 6 months
Calcium intake more than 1500 mg per day
Using hormone therapy, antidiabetic, or anti-obesity medications within the last 6 months
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Insulin resistance. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Eliza.
- Secondary Outcome Measures
Name Time Method Insulin. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Elisa kit.;Insulin sensitivity. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Using QUICKI formula.;Triglycerides. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Enzymatic kit.;Total cholesterol. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Enzymatic kit.;VLDL. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Enzymatic kit.;LDL-cholesterol. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Enzymatic kit.;HDL-cholesterol. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Enzymatic kit.